- Gilead Sciences experiences a slight decline in overall product sales but sees a growth in HIV treatments.
- Analysts predict a moderate upside potential with a one-year price target average.
- Current valuations suggest a notable downside based on GuruFocus' GF Value metric.
Gilead Sciences Inc. (NASDAQ: GILD) recently released its mixed first-quarter earnings for 2025. The biopharmaceutical giant experienced a minor 1% decline in overall product sales, including its COVID-19 treatment, Veklury. This dip is attributed to a decrease in COVID-19 hospitalizations. However, on a positive note, Gilead's HIV product line showed resilience, with sales increasing by 6% year-over-year. Notably, Biktarvy, one of their leading HIV treatments, posted a 7% increase in sales. Looking ahead, the company projects total product sales ranging from $28.2 billion to $28.6 billion for the year.
Wall Street Analysts' Forecast
According to the one-year price target projections from 24 analysts, Gilead Sciences Inc. (GILD, Financial) has an average target price of $112.27. This reflects a high estimate of $140.00 and a low estimate of $82.00. The average target indicates a potential upside of 5.77% from the current trading price of $106.15. For a comprehensive breakdown of these estimates, visit the Gilead Sciences Inc (GILD) Forecast page.
Brokerage Recommendations
The consensus among 30 brokerage firms places Gilead Sciences Inc. (GILD, Financial) at an average recommendation rating of 2.1, which qualifies as "Outperform." This rating scale ranges from 1, indicating a Strong Buy, to 5, which denotes a Sell.
Valuation Insights
Based on GuruFocus estimates, the one-year estimated GF Value for Gilead Sciences Inc. (GILD, Financial) is calculated to be $80.51. This suggests a downside of 24.15% from its current market price of $106.15. The GF Value represents GuruFocus' calculation of the stock's fair value, derived from historical trading multiples, past business growth, and projected future performance. For a detailed valuation analysis, please refer to the Gilead Sciences Inc (GILD) Summary page.
